tbuckley/cabot-search huggingface dataset:
Abstract ES6-3: ES6-3 Radiation implications post neoadjuvant therapy
Authors: BD Smith
Journal: Cancer Research (2017)

Abstract Neoadjuvant therapy offers unique challenges and opportunities for the radiation oncologist. Classical indications for radiation have been rooted in the pathologic analysis of tissue resected prior to treating the patient with systemic therapy. However, in patients treated with neoadjuvant therapy, pathologic findings are frequently altered by the administration of systemic therapy, and thus classical indications for radiation may be clouded. Nevertheless, the degree of response to neoadjuvant therapy offers a novel prognostic factor which reflects intrinsic tumor biology and affords the opportunity for a new, precision approach to risk stratification and radiation therapy treatment decision making. To maximally capitalize on the information gained from treating a patient with neoadjuvant chemotherapy, patients must be meticulously staged, preferably by a multidisciplinary team, prior to initiation of systemic therapy. Ultrasound of the regional nodal basins including the low axillary, infraclavicular, supraclavicular, and internal mammary nodal chains with ultrasound-guided fine needle aspiration of radiographically abnormal nodes enables detailed mapping of the local-regional disease extent. Cross-sectional imaging with CT and/or PET/CT is also helpful to permit customized radiation field design after systemic therapy and surgery. These imaging studies are invaluable to the radiation oncologist and allow for optimal field design to facilitate cure. Additionally, nodal surgery prior to administration of systemic therapy, while helpful in documenting pre-treatment nodal status, results in loss of ability to accurately assess response to chemotherapy in the lymph nodes and is thus avoided in our practice. The available evidence indicates that patients experiencing a pathologic complete response have exceptional local-regional control. Accordingly, current randomized trials are exploring whether either radiation or surgery can be de-escalated within this context. In contrast, for patients with significant residual tumor burden following neoadjuvant chemotherapy, local-regional control outcomes are suboptimal for those with triple negative or HER2 positive disease. Novel strategies to escalate therapy with radiosensitizers or other biologic agents are needed for this population. Citation Format: Smith BD. ES6-3 Radiation implications post neoadjuvant therapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr ES6-3.
Hepatitis A outbreak among men who have sex with men (MSM) predominantly linked with the EuroPride, the Netherlands, July 2016 to February 2017
Authors: Gudrun S Freidl, Gerard JB Sonder, Lian PMJ Bovée, Ingrid HM Friesema, Gini GC van Rijckevorsel, Wilhelmina LM Ruijs, Frank van Schie, Evelien C Siedenburg, Jyh-Yuan Yang, Harry Vennema
Journal: Eurosurveillance (2017)

Between July 2016 and February 2017, 48 male cases of hepatitis A were notified in the Netherlands. Of these, 17 identified as men who have sex with men (MSM). Ten of the 13 cases for whom sequencing information was available, were infected with a strain linked with the EuroPride that took place in Amsterdam in 2016. This strain is identical to a strain that has been causing a large outbreak among MSM in Taiwan.
Role of interleukin 33 in chronic rhinosinusitis
Authors: Roma Sehmi
Journal: Thorax (2017)

Chronic rhinosinusitis (CRS) is a heterogenous airways disease characterised by inflammation of the upper airways and sinuses that persists for at least 12 weeks. CRS is frequently divided into two endotypes based on the presence or absence of nasal polyps (NPs): CRS with NPs (CRSwNP) and CRS without NPs (CRSsNP). Inflammatory patterns in the two groups are different and studies indicate that CRSsNP is dominated by a type 1 inflammatory profile associated with increased interferon (INF)-γ and tumour necrosis factor (TGF)-β expression and neutrophilic inflammation.1 By comparison, type 2 inflammatory responses characterised by interleukin (IL) 4, IL-5, IL-13 cytokine expression and eosinophilic inflammation are features of CRSwNP.1 This categorisation may, however, be oversimplified as recent studies show that this may be subject to racial and regional differences.2 ,3 While the majority of Caucasian patients sampled in the USA and Europe have a pronounced infiltration of eosinophils and expression of IL-5 in the NPs, patients with CRSwNP in East Asian countries including Japan, Korea and China, exhibit a mixed inflammatory profile. About half the Asian patients with CRSwNP exhibit an eosinophilic chronic rhinosinusitis (ECRS) while the rest have a non-eosinophilic more neutrophilic or mixed inflammatory chronic rhinosinusitis (non-ECRS) characterised by type 1 dominant inflammation. Although a number of hypotheses have been proposed regarding the pathogenesis of CRSwNP, the precise molecular mechanisms remain unclear and likely lie beyond rudimentary clinical classifications of CRS. An emphasis on defining CRS endotypes based on distinct functional or pathobiological mechanisms of disease may be more effective at identifying patient groups that would respond to therapeutic interventions targeting specific proinflammatory mediators or infectious agents that trigger the disease pathology.

The inflammatory profile of CRSsNP is largely type 1, although there are discrepancies over which isoforms of TGF-β are increased per se and in what …
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients.
Authors: Francesca Gay, Patrizia Falco, Claudia Crippa, Anna Marina Liberati, Francesca Patriarca, Clotilde Cangialosi, Vincenzo Capparella, Agostina Siniscalchi, Manuela Rizzo, Luca De Rosa, Antonietta Pia Falcone, Simona Caltagirone, Sara Bringhen, Paolo Corradini, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2009)
Genome Wide-DNA Profiling of Richter’s Syndrome-Diffuse Large B-Cell Lymphoma (RS-DLBCL): Differences with De Novo DLBCL and Possible Mechanisms of Transformation from Chronic Lymphocytic Leukemia (CLL).
Authors: Francesco Bertoni, Marta Scandurra, Michaela Cerri, Clara Deambrogi, Paola MV Rancoita, Silvia Rasi, Francesco Forconi, Maurilio Ponzoni, Santiago Montes-Moreno, Miguel A. Piris, Giorgio Inghirami, Andrea Rinaldi, Emanuele Zucca, Ivo Kwee, Gianluca Gaidano, Davide Rossi
Journal: Blood (2008)
Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Authors: Naveen Pemmaraju, Andrew A. Lane, Kendra L. Sweet, Anthony S. Stein, Sumithira Vasu, William Blum, David A Rizzieri, Eunice S. Wang, Madeleine Duvic, Janice Chen, Shay Shemesh, Peter McDonald, Christopher L. Brooks, Jeffrey E. Lancet, Hagop M. Kantarjian, Marina Konopleva
Journal: Blood (2016)
Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival
Authors: Douglas E Joshua, Mark S Hertzberg, Bradley Auguston, Andrew Spencer, Noemi Horvath, John Bashford, Lynda J Campbell, Eleanor Ashurst, Jacquelyn Wade, Michael C. Copeman, Belinda E Butcher, Miles Prince
Journal: Blood (2012)
Abstract P2-01-34: Identification and biopsy of sentinel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasound (CEUS) in pre-operative breast cancer patients: Early collective experience of the UK Microbubble Group
Authors: KL Cox, N Sharma, A Leaver, A Lim, P Mills, J Weeks, A Sever, M Hashem, T DeSilva
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Clinical Efficacy of the Rivbd Combination for Refractory/Relapsed (R/R) Mantle Cell Lymphoma (MCL) Patients: A Retrospective Study of the French Lysa Group
Authors: Caroline Régny, Sandra Malak, Guillaume Manson, Clementine Sarkozy, Aline Clavert, Charles Herbaux, Adrien Chauchet, Eric Jourdan, Laurence Sanhes, Pascal Godmer, Laurent Pascal, Katell Le Du, Laurent Sutton, Laurent Voillat, Jehan Dupuis, Bruno Anglaret, Remy Gressin
Journal: Blood (2016)
Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency
Authors: Shi Hu, Wenyan Fu, Tian Li, Qingning Yuan, Feifei Wang, Gaojian Lv, Yuanyuan Lv, Xiaoyan Fan, Yafeng Shen, Fangxing Lin, Ying Tang, Xuting Ye, Yongji Yang, Changhai Lei
Journal: Science Translational Medicine (2017)

An anti-EGFR/Notch antibody limits acquired resistance to EGFR inhibitors and radiation by reducing tumor-initiating cell frequency.
In Vivo Deficiency of Both Transcription Factors, C/EBPbeta and C/EBPepsilon, Results in Lack of Cytokine Response and a High Susceptibility for Overwhelming Infections.
Authors: Nils Heinrich Thoennissen, Tadayuki Akagi, Jee Hoon Song, Gabriela B. Iwanski, H. Phillip Koeffler
Journal: Blood (2009)
Abstract A62: Unjamming and spreading of a cellular aggregate as a model of breast cancer migration
Authors: Karin Wang, Jeffrey J. Fredberg
Journal: Cancer Research (2017)

Abstract Traditional understanding holds that metastasis begins as tumor cells undergo epithelial-to-mesenchymal transition (EMT) to migrate and escape. Recent studies suggest that EMT is not necessary for metastasis, however. Tumor cells may retain their epithelial phenotype to migrate collectively during metastasis. But if EMT is not the crucial permissive step, what is? Our group recently discovered cellular jamming; a process by which an epithelial layer is dormant, non-migratory, and solid-like, corresponding to the jammed state, but in other circumstances becomes active, migratory, and fluid-like, corresponding to the unjammed state. Therefore, based on this phenomenon, do breast cancer cells unjam before they can collectively migrate and metastasize? Spheroidal aggregates of MCF10A and MDA-MB-231 cells spreading on collagen-coated polyacrylamide gels, modeling normal and malignant breast epithelium, respectively, were used to investigate cell jamming, cell-matrix adhesion, and associated traction forces. Compared with MCF10A spheroids, MDA-MB-231 spheroids permeated more rapidly onto gels, generated largely localized traction forces, and dissociated to spread more rapidly outwards. These results suggest MDA-MB-231 cells are more susceptible to unjamming and collective migration. This work will provide a new framework by which to explain collective cellular behavior of normal and malignant breast epithelium. Citation Format: Karin Wang, Jeffrey J. Fredberg. Unjamming and spreading of a cellular aggregate as a model of breast cancer migration. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr A62.
Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities
Authors: Julia Chang, Gefei A. Zhu, Christine Cheung, Shufeng Li, Jinah Kim, Anne Lynn S. Chang
Journal: JAMA Dermatology (2017)

Response to programmed death 1 (PD-1) inhibitors has been associated with programmed death ligand 1 (PD-L1) expression levels in several cancers, but PD-L1 expression and its clinical significance in basal cell carcinoma (BCC) are unknown to date.To assess PD-L1 expression in treatment-naive and treated BCCs.This investigation was a cross-sectional study at a single academic tertiary referral center. Immunohistochemical staining on formalin-fixed BCCs from a dermatology clinic were examined in masked fashion by a dermatopathologist and a dermatologist. The study dates were March 31, 2014, to June 7, 2016.Treated BCCs (including those recurrent after surgery, radiotherapy, systemic chemotherapy, or topical chemotherapy) vs treatment-naive BCCs.Percentage of tumor cells and tumor-infiltrating lymphocytes (TILs) with PD-L1 expression, intensities of expression, and association with treatment modalities.Among 138 BCCs from 62 patients (43 males and 19 females; mean [SD] age at biopsy, 61.6 [13.7] years), 89.9% (124 of 138) were positive for PD-L1 expression in tumor cells, and 94.9% (131 of 138) were positive for PD-L1 expression in TILs, defined as greater than 5% positive immunohistochemical staining in the respective cell populations. The PD-L1 immunohistochemical staining intensity of 78 treated BCCs compared with 60 treatment-naive BCCs was significantly different in tumor cells (32% vs 7%, P = .003) and TILs (47% vs 18%, P = .008) after adjusting for the age at diagnosis. In a multivariable model adjusting for age, sex, and BCC location, PD-L1 staining intensity in tumor cells increased with the number of distinct prior treatment modalities (median, 0.12; interquartile range, 0.03-0.20; P = .007).Our data suggest that PD-1 immunotherapy may have activity against BCCs, including in those that have been previously treated. This hypothesis needs to be tested in future clinical trials.
Transformation of Chronic Lymphocytic Leukemia Towards Richter´s Syndrome Is Induced By AKT Activation
Authors: Nadine Nickel, Mona Al-Maarri, Martin Pal, Andreas Roth, Gero Knittel, Carmen D. Herling, Nina Reinart, Stephan Schäfer, Elena M Hartmann, Andreas Rosenwald, Wolfram Klapper, Reinhard Büttner, Marco Herling, Jens Bruening, Christian Reinhardt, Michael Hallek, Thomas Wunderlich, Christian Pallasch
Journal: Blood (2016)
Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.
Authors: Frans Opdam, Vincent O. Dezentje, Jan den Hartigh, Henk-jan Guchelaar, Trees Hessing, Tahar van der Straaten, Robert Vree, Erdogan Batman, Eduard Maartense, Carolien H. Smorenburg, Anneke Zeillemaker, J. A. C. Brakenhoff, Maartje Los, Philomeen Kuijer, Hein Putter, Anne-Sophie Dieudonné, Patrick Neven, Cornelis J. H. Van De Velde, J. W. R. Nortier, Hans Gelderblom
Journal: Journal of Clinical Oncology (2013)

595 Background: Breast cancer patients with absent or reduced CYP2D6 activity may benefit less from tamoxifen treatment because of impaired biotransformation to the active metabolite endoxifen. We investigated whether a temporary one-step dose escalation of tamoxifen in CYP2D6 poor (PM) and intermediate metabolizers (IM) could increase endoxifen serum concentration to a similar level observed in CYP2D6 extensive metabolizers (EM) without increasing toxicity. Methods: From a prospective study population of early breast cancer patients using tamoxifen, 12 CYP2D6 poor and 12 intermediate metabolizers were selected and included in a one-step tamoxifen dose escalation study during two months. The escalation dose (120 mg maximum) was calculated by multiplying the individual’s endoxifen level divided by the median endoxifen concentration (33.7 nM) observed in CYP2D6 extensive metabolizers by 20 mg. Toxicity was assessed and all patients returned to the standard dose of 20 mg after two months. Results: Tamoxifen dose escalation in CYP2D6 poor and intermediate metabolizers significantly increased endoxifen concentrations (PMs: from 8.0 nM to 27.3 nM, p&lt;0.001; IMs: from 17.8 nM to 30.3 nM, p=0.002) without increasing side effects. In intermediate but not in poor metabolizers dose escalation increased endoxifen to levels comparable with those observed in extensive metabolizers using tamoxifen 20 mg once daily (33.7 nM). Conclusions: CYP2D6 genotype and endoxifen guided tamoxifen dose escalation increased endoxifen concentrations without increasing short term side effects. Whether such tamoxifen dose escalation is effective and safe in view of long term toxic effects is uncertain and needs to be explored. Clinical trial information: NTR1509.
Expectations and Concerns Towards New Extended Half-Life (EHL) Products - Results of Surveys Among Haemophilia Patients from the Dach Region
Authors: Sylvia von Mackensen, Werner Kalnins, Hostettler Lino, Krucker Joerg, Manuela Albisetti, Josef Weiss, Ingrid Pabinger, Johannes Oldenburg
Journal: Blood (2016)
A Clinical and Biomarker Scoring System to Predict the Presence of Obstructive Coronary Artery Disease
Authors: Nasrien E. Ibrahim, James L. Januzzi, Craig A. Magaret, Hanna K. Gaggin, Rhonda F. Rhyne, Parul U. Gandhi, Noreen Kelly, Mandy L. Simon, Shweta R. Motiwala, Arianna M. Belcher, Roland R.J. van Kimmenade
Journal: Journal of the American College of Cardiology (2017)
Predictors of Sustained Virological Response After Antiviral Therapy for Chronic Hepatitis C In Patients with Hemophilia: The Role of the Interleukin-28B (IL28B) Polymorphism
Authors: Maria Elisa Mancuso, Alessio Aghemo, Elena Santagostino, Maria Grazia Rumi, Raffaele Bruno, Massimo Colombo, Pier Mannuccio Mannucci
Journal: Blood (2011)
PP77. NORCARDIA INFECTED GLIOBLASTOMA MULTIFORME CAUSING DIAGNOSIS DELAY
Authors: Dr Eno Umotong
Journal: Neuro-Oncology (2017)

INTRODUCTION: Norcardosis is a rare infection most frequently caused by the gram positive, acid-fast bacteria Norcardia Asteroides. The lungs and skin are the most commonly affected organs though cerebral infection is a complication of 15–40% of systemic norcardiosis. Here, the first case is reported of the diagnosis of Glioblastoma Multiforme being delayed due to the distraction from the accompanying Norcardiosis Case Report: In October 2015, a 65-year-old man with a background of previous DVT and bilateral pulmonary embolisms presented to the University Hospitals Coventry and Warwickshire (UHCW) with a 3 day history of worsening headache. Imaging revealed multiple ring enhancing lesions in the deep right temporal lobe, right frontal, both parietal lobes and cerebellum. Post operative histology samples suggested a diagnosis of Norcardia for which he received Co-trimoxazole and Linezolid. However, previously excised lesions re-appeared, old lesions progressed and new lesions developed requiring multiple re-visits to the operating room. Histology samples indicated an infective process until the 5th intra-operative sample grew Glioblastoma WHO grade 4. The patient received a sixth operation and currently remains on antibiotic therapy. He is responding well and is neurologically intact. DISCUSSION: There are few cases of an intracerebral neoplasm being colonated by Norcardia. The literature suggests that various techniques using MR perfusion, diffusion imaging and spectroscopy are useful in differentiating tumours from abscesses however, there is no guarantee that when both pathologies co-exist differentiation is possible. Further studies are needed to evaluate this.
<i>APC</i> allele-specific expression in carriers of Ashkenazi Jewish mutation I1307K
Authors: G. Capella, E. Castellsague, G. Rennert, S. Gruber
Journal: Journal of Clinical Oncology (2009)

e22181 Background: I1307K is a missense APC variant with incomplete penetrance that has been found in 6% of Jewish Ashkenazi population and confers a two-fold increased risk to develop multiple adenomas and colorectal tumours. It is believed that it creates a hypermutable region within the gene that leads to an accumulation of mutations. It remains unknown whether the presence of this mutation modifies APC expression. Our goal was to study whether allele-specific expression (ASE) of I1307K is present at the germline and tumoral level. Methods: Paired germline/carcinoma RNA and DNA was studied from eleven I1307K carriers. To analyze changes in the mutant/wt allelic ratio we used single nucleotide primer extension (SNuPE) for the I1307K and the rs2229992 APCcoding SNP. Fourteen controls were also analyzed. Results: No germline allele specific expression was found in I1307K carriers (range=0.954–1.173). Significant ASE was observed in 8 of the 10 carcinomas analyzed. In 4 cases the I1307K allele was overexpressed (range=2.51–9.51) and in 4 cases was underexpressed (range=0.09–0.28). Tumor ASE correlated with the DNA mutant/wt allelic dose. Conclusions: I1307K variant is not associated with allelic specific expression at the germline level. I1307K overexpression is not selected for during tumor progression. No significant financial relationships to disclose.
Abstract P5-16-12: Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer
Authors: N Gupta, E Giblin, C Leagre, S Longmire-Cook, T Tigges, J Compton, T Dugan, R liebross, S Givens, K Schmidt, R Paul, R Trivedi, B Smith, D Reeves, J Hanson, T Schmidt
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
Substance Use Terminology
Authors: Charles Moser
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal